General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-06-20 | 2024-03 | 0 | N/A | N/A | N/A |
2024-04-02 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -0.02 | N/A | N/A |
2023-08-11 | 2023-06 | 0 | -0.03 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -0.05 | N/A | N/A |
2023-03-21 | 2022-12 | 0 | -0.11 | N/A | N/A |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-11-29 | BHALLA AMIT | Director | 71.82K | Stock Award(Grant) |
2021-06-29 | BRUCK CLAUDINE | Director | 16.52K | Stock Award(Grant) |
2022-11-29 | CAPPELLO ALEXANDER L | Director | 67.73K | Stock Award(Grant) |
2021-11-29 | FARB THOMAS F | Director | 33.42K | Stock Award(Grant) |
2022-09-08 | ROSOL MICHAEL STANLEY | Officer | 67.05K | Stock Award(Grant) |
2023-06-28 | SCOTT JOHN K JR. | Director and Beneficial Owner of more than 10% of a Class of Security | 31.77M | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Vanguard Group, Inc. (The) | 286.64K | 31.99K | 0.82% |
2023-03-30 | Renaissance Technologies, LLC | 238.13K | 26.58K | 0.68% |
2023-03-30 | Allred Capital Management, LLC | 164.74K | 18.38K | 0.47% |
2023-03-30 | Millennium Management Llc | 128.76K | 14.37K | 0.37% |
2023-03-30 | Blackrock Inc. | 112.88K | 12.60K | 0.32% |
2023-03-30 | Geode Capital Management, LLC | 104.62K | 11.68K | 0.30% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | Vanguard Total Stock Market Index Fund | 396.92K | 44.30K | 1.21% |
2022-12-30 | Vanguard Extended Market Index Fund | 276.49K | 30.86K | 0.84% |
2022-12-30 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 102.44K | 11.43K | 0.31% |
2023-02-27 | Fidelity Extended Market Index Fund | 69.66K | 7.77K | 0.21% |
2023-02-27 | Fidelity Series Total Market Index Fund | 17.81K | 1.99K | 0.05% |
2023-02-27 | iShares Core S&P Total U.S. Stock Market ETF | 7.45K | 830.00 | 0.02% |
Split | Date |
---|---|
1 : 20 | 2019-04-26 |
$MULN is about to go
$NAVB such good news why isn’t this exploding!!!
Where is the $NAVB news?
$NAVB hoping for news today
Loading up
When will news be released?
Let’s see what happens tomorrow
What is going on
Yup something is going on
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. $IBIO shares price in past pandemics 15$-55$, $IBIO is known for FastPharming has applications far beyond producing a COVID-19 vaccine. An example of this potential was a deal signed in October with Safi Biosolutions. The agreement will see iBio’s FastPharming system used in the bioprocessing of Safi’s blood cell therapy products. FastPharming has the potential to be part of many such deals in the future. $IBIO conference is Today (there are speculation of possible contract or partnership)
It will take 6 months to get back to 4$
Push it babe
If John is selling his shares, why shouldn’t I?